Eledon Pharmaceuticals (ELDN) Assets Average (2014 - 2026)

Eledon Pharmaceuticals (ELDN) has 13 years of Assets Average data on file, last reported at $157.8 million in Q1 2026.

• Quarterly Assets Average fell 6.8% year-over-year to $157.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.8 million (down 6.8% YoY) and the FY2025 annual result came in at $173.2 million, up 30.0% from the prior year.
• Assets Average rose to $157.8 million in Q1 2026, from $149.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $169.4 million in Q1 2025 to a low of $84.9 million in Q1 2024.
• A 5-year average of $128.8 million and a median of $137.4 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average sank 47.25% — and 2025, when it surged 99.38%.
• Tracing ELDN's Assets Average over 5 years: stood at $121.2 million in 2022, then decreased by 23.62% to $92.6 million in 2023, then soared by 57.71% to $146.0 million in 2024, then increased by 2.36% to $149.4 million in 2025, then increased by 5.62% to $157.8 million in 2026.
• The last three Assets Average figures came in at $157.8 million (Q1 2026), $149.4 million (Q4 2025), and $137.4 million (Q3 2025), per Business Quant data.